2 Perceived Challenges of COVID-19 Infection Prevention and Control

3 **Preparedness: A Multinational Survey**

4	Ermira Tartari ^{1,2,3¶} ; Joost Hopman ^{4¶} ; Benedetta Allegranzi ^{2,5} ; Bin Gao ^{6,7} ; Andreas
5	Widmer ⁸ ; Vincent Chi-Chung Cheng ^{9,10} ; Shuk Ching Wong ¹⁰ ; Kalisvar
6	Marimuthu ^{11,12,13} ; Folasade Ogunsola ^{14,15} ; Andreas Voss ^{4,16,17*} ; on behalf of the
7	International Society of Antimicrobial Chemotherapy Infection and Prevention
8	Control (ISAC-IPC) Working Group^
9	
10	¹ Infection Control Program and WHO Collaborating Centre on Patient Safety,
11	Geneva University Hospitals and University of Geneva Faculty of Medicine, Geneva,
12	Switzerland
13	² Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva,
14	Switzerland
15	³ Faculty of Health Sciences, University of Malta, Msida, Malta
16	⁴ Radboudumc Center for Infectious Diseases, Department of Medical Microbiology,
17	Radboud University Medical Center, Nijmegen, The Netherlands
18	⁵ Infection Prevention and Control Technical and Clinical Hub, Department of
19	Integrated Health Services, World Health Organization, Geneva, Switzerland
20	⁶ Infectious Disease Unit, Tianjin 4 th Centre Hospital, Tianjin, China
21	⁷ Graduate School, Tianjin Medical University, Tianjin, China
22	⁸ Division of Infectious Diseases and Hospital Epidemiology, University Hospital

23 Basel, Switzerland

- ⁹ Department of Microbiology, Queen Mary Hospital, The University of Hong Kong,
- 25 Hong Kong, Special Administrative Region, China
- ²⁶ ¹⁰ Infection Control Team, Queen Mary Hospital, Hong Kong West Cluster, Hospital
- 27 Authority, Hong Kong, Special Administrative Region, China
- 28 ¹¹ Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore
- 29 ¹² National Centre for Infectious Diseases, Singapore, Singapore
- 30 ¹³ Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
- 31 Singapore
- ³² ¹⁴ Department of Medical Microbiology and Parasitology, College of Medicine of the
- 33 University of Lagos, Lagos, Nigeria
- 34 ¹⁵Infection Control Africa Network
- 35 ¹⁶ Department of Medical Microbiology and Infectious Diseases, Canisius-
- 36 Wilhelmina Hospital (CWZ), Nijmegen, The Netherlands
- 37 ¹⁷ REshape Center for Innovation, Radboudumc, Nijmegen, The Netherlands
- 38
- 39 These authors contributed equally to this work.
- 40 ^Membership of the ISAC-IPC Working Group is listed in the Acknowledgments.
- 41
- 42 Word count: 3603; 3 Tables; 2 Figures
- 43 *Corresponding author:*
- 44 Ermira Tartari, MSc
- 45 Infection Prevention and Control,
- 46 University Hospitals of Geneva
- 47 Rue Gabrielle-Perret-Gentil, 4
- 48 CH-1211 Geneva 14, Switzerland

- 49 Tel. +356-99873798 ; E-mail ermira.tartari@gmail.com

52	Abstract
53 54	Objectives: Implementation of effective infection prevention and control (IPC)
55	measures is needed to support global capacity building to limit transmission of
56	coronavirus disease 2019 (COVID-19) and mitigate its impact on health systems. We
57	assessed the perceptions of healthcare workers on the current global IPC preparedness
58	measures for COVID-19.
59	Methods: A cross-sectional survey using an electronic survey was circulated between
60	February 26, 2020, and March 20, 2020, to IPC professionals during COVID-19
61	pandemic. The survey addressed the presence of COVID-19 guidelines as well as
62	specific IPC preparedness activities in response to the outbreak.
63	Findings: In total, 339 IPC professionals spanning 63 countries in all 6 World Health
64	Organization (WHO) regions, mostly from tertiary care centres participated. Of all
65	participants, 66.6% were aware of the existence of national guidelines to prevent
66	COVID-19. A shortage of PPE supplies was reported by 48% (ranging from 64.2% in
67	low-income countries to 27.4% in high-income countries); 41.5% of respondents
68	considered that the media had an impact on guideline development and 63.6%
69	believed that guidelines were based on maximum security rather than on evidence-
70	based analyses. 58.5% and 72.7% of participants believed that healthcare facilities
71	and community settings respectively were not sufficiently prepared.
72	Conclusion: Results revealed lack of guidelines and concerns over insufficient PPE
73	supply in both high- and low-income countries. Our findings should alert national
74	health authorities to ramp up the implementation of IPC measures and focus on long-

term preparedness and readiness for future pandemics, likely requiring government

76 funds rather than reliance on healthcare institutions.

77 Keywords: COVID-19; SARS-CoV-2; 2019-nCoV; coronavirus disease 2019

78 infection prevention and control; personal protective equipment; PPE; media

79

80 Introduction

81 The emergence of the unprecedented novel coronavirus disease 2019 (COVID-19)

82 outbreak in China[1,2] and its rapid spread worldwide is of major global concern to

- 83 public health and national economies.[3] On January 30, 2020, the World Health
- 84 Organization (WHO) declared COVID-19 as a public health emergency of

85 international concern under the International Health Regulations (2005)[4] and on

86 March 11, 2020, COVID-19 was declared a global pandemic.[5] As of 19 April,

87 2020, over 7 390 702 cases and 417 731 deaths have been reported across the

88 globe.[3]

89

90 Acknowledgment of the major threat represented by this new virus prompted WHO to 91 convene a global research roadmap forum on 11/12 February 2020 with leading 92 health experts to assess the evidence about COVID-19 disease, identify gaps and 93 prioritize research needed in a number of critical areas, to make rapid progress in the 94 fight against the virus.[6] Infection prevention and control (IPC) is one of the critical 95 areas identified as a priority for rapid research action. Since the beginning of the 96 outbreak, WHO's leadership recommended all countries to rapidly develop national 97 preparedness capacities for the detection, investigation and management of suspected 98 or confirmed COVID-19 cases and to implement the WHO infection prevention and 99 control (IPC) core components in order to respond effectively.[7]

101	Previous experience of outbreaks due to the severe acute respiratory syndrome
102	coronavirus (SARS-CoV), Ebola, and the Middle East respiratory syndrome
103	coronavirus (MERS-CoV) including the ongoing large-scale outbreak of COVID-19,
104	has shown a high incidence of transmissibility of health care-associated infections and
105	outbreaks affecting healthcare workers (HCWs) who are at the forefront of these
106	crises, illustrating the importance of being prepared.[8–11] Up to 24 February 2020
107	(day 56), the National Health Commission of the People's Republic of China reported
108	that 3387 HCWs were infected with COVID-19, resulting in 22 (0.6%) deaths.[12] In
109	Italy, according to the estimates of the National Public Health Institute, as of April 15,
110	out of a total of 155 467 positive cases, 16 650 were HCWs,[13] with the numbers
111	increasing over time.

112

113 Methods

114 **Objectives**

115 The main objectives of the study were to gain a rapid insight into the preparedness of

116 healthcare facilities and investigate current global practices and perceptions among

117 IPC professionals concerning the prevention and control of COVID-19 so as to

118 identify opportunities for improving practices globally.

119

120 Setting and participants

121 From February 26 through March 20, 2020, the International Society of Antimicrobial

122 Chemotherapy (ISAC) Working Group for IPC in partnership with Infection Control

123 Africa Network (ICAN) launched a cross-sectional, self-administered web-based

124 survey of IPC specialists working in healthcare facilities to explore IPC measures for

125	COVID-19 preparedness. ISAC Working Group for IPC has affiliated members and
126	IPC representatives from 57 countries worldwide. The IPC Working Group has been
127	initiated to support international research projects and for standardization of
128	guidelines and IPC measures across countries worldwide. To achieve coverage across
129	low- and middle-income countries, agreement was reached to form a working party
130	with ICAN. An online link to the electronic questionnaire was distributed through
131	ISAC and ICAN members and networks and also via social media platforms inviting
132	IPC experts from each continent and country to participate. The link to the web-based
133	survey was made accessible on the societies' websites. IPC specialists including
134	microbiologists, infectious diseases physicians, nurses, antimicrobial pharmacists and
135	other specialists working in healthcare facilities preparing for the detection,
136	investigation and management of confirmed and suspected COVID-19 patients were
137	invited to participate. Participants were enrolled through a non-random, convenience
138	sampling method. Due to the non-probabilistic sampling nature, it was not possible to
139	determine the statistical representatives of the sample.
140	The participants enrolled by a web-survey where information about the study's
141	purpose was provided. Participants were informed that the purpose of the survey was
142	intended to help inform the current progress of countries with IPC measures and
143	preparedness plans for preventing COVID-19. There were no exclusion criteria.
144	Participation in this study was voluntary and anonymous. Participants completed a
145	web-based questionnaire tool, generated using Survey Monkey platform
146	(SurveyMonkey®, San Mateo, CA, USA). Pre-testing of the platform was performed
147	with 20 users from all six regions to evaluate usability and detect technical failures.
148	

149 The study was exempted by the Radboud University Medical Center (The

150 Netherlands) as it did not fall within the remit of the Medical Research Involving

151 Human Subjects Act (NL2020-6262). The study follows the Strengthening the

152 Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline

- 153 (Supplementary file 1).
- 154

155 Survey design, administration and analysis

156 The survey instrument was a self-designed questionnaire, compiled by IPC scientists

and experts participating in the WHO COVID-19 global research and innovation

158 roadmap forum and based on the priorities and thematic areas identified at the

159 forum.[6] After assessing content validity, the instrument was pilot tested among 10

160 IPC opinion leaders in six countries, in three WHO regions (Europe, Africa and

161 South-East Asia) to evaluate its acceptance and reproducibility. The questionnaire

162 was created in English to gain insight into the preparedness of healthcare facilities.

163 Two study investigators translated the English version of the instrument to Chinese.

164 To confirm that the Chinese translation was reliable, the instrument was back

165 translated to English. The final instrument (Supplementary file 2) was available in

166 English and Chinese. The questionnaire included 47 items in total covering six

167 dimensions addressing: 1) geographic location, demographics and healthcare facility

168 characteristics; 2) the presence of national/regional/local COVID-19 guidelines; 3)

169 personal protective equipment (PPE) type and supplies in healthcare facilities; 4) the

170 role of environmental contamination; 5) preparedness for COVID-19 activities; and 6)

- 171 the influence of media on preparedness plans. The instrument included dichotomous
- 172 (yes/no) closed-ended questions and for one section participants were asked to

173 provide their degree of agreement with each item (Agree and Disagree). All responses

to questions were allocated a numerical score on the survey platform. Submission of
responses via the online platform (SurveyMonkey®, San Mateo, CA, USA) indicated
agreement to participate. It was decided to use all entries that contained information
about COVID-19 IPC measures and activities, even if there were missing responses
for some of the items. Entries with no demographic information were excluded.

179

180 Statistical Analysis

181 Descriptive statistics were used to analyse the survey data. For descriptive purposes,

182 medians with IQR, cumulative frequencies or 95% confidence intervals (CI) were

- 183 calculated where appropriate. Means and ranges were aggregated at UN regional level
- 184 (Africa, the Americas, Eastern Mediterranean, Europe, Southeast Asia, Western
- 185 Pacific) and country income group according to the World Bank classification (high-
- 186 income, upper-middle-income, lower-middle-income and low-income).[14] A p-value

187 of less than 0.05 was considered significant. Analyses were performed using R

188 version 3.5.1 (R Core Team. R: A language and environment for statistical

189 computing. R Foundation for Statistical Computing, Vienna, Austria; 2017;

190 <u>https://www.R-project.org/</u>).

191 **Results**

192 Characteristics of Survey Respondents

- 193 A total of 349 responses were received; 10 were excluded as no demographic
- 194 information was provided. A sample of 349 participants selected from the two
- 195 organizations which include approximately 800 IPC specialists guarantees a
- 196 maximum margin of error of 3.94% assuming a 95% confidence level. The 339
- eligible responses were coming from 63 countries across the 6 regions: Africa, 113;
- 198 Europe, 92; Southeast Asia, 72; the Americas, 33; Eastern Mediterranean, 15;

199 Western Pacific, 14). They represented 113 responses from high-income countries

200 (HICs), 99 from upper-middle-income countries (UMICs), 71 from lower-middle-

201 income countries (LMICs) and 56 from low-income countries (LICs). Response rate

by profession included 190 IPC physicians (56.0%); 113 IPC nurses (33.3%) and 36

- 203 other professionals, including pharmacists and public health specialists. Healthcare
- facilities represented in the survey were mostly tertiary care centres (46%) (Table 1).

205

206 COVID-19 Guidelines

207 Respondents reported that either national (226/339; 66.6%; 95% CI, 61.6-71.6), local

208 or regional (182/339; 53.6%; 95% CI, 48.3-59) guidelines on the prevention and

209 management of COVID-19 were available, but with a significant variation according

210 to region/income level, e.g. HICs (65.5%; 95% CI, 48.2-82.8) were more likely to

have national guidelines available than LICs (7.6%; 95% CI, 0-22.1) (P < 01) (figure

212 1; Table 2). When guidelines were not available, respondents mainly adopted

213 international guidelines (72/106; 67.9%). Adopted guidelines were based on those

from WHO (42.4%), the European Centre for Disease Prevention and Control

215 (ECDC) 4.7%, Public Health England (PHE) 4.7%, the US Centers for Disease

216 Control and Prevention (CDC) (3.7%) and a combination of WHO, ECDC, CDC

and/or PHE (12.2%). The remaining respondents did not know. Almost all

respondents (259/269; 96.2%; 95% CI, 94-98.5) affirmed that guidelines included

219 hand hygiene as an important measure (Fig.1, Table 2).

220

221 Personal Protective Equipment

- More than half (214/339; 63.1%; 95% CI, 57.9-68.2) of respondents reported that
- 223 guidelines for healthcare facilities addressed PPE use, with a significant variation by
- region/income level. (Fig. 1, Table 2).
- 225

226 Facemasks

- 227 Participants reported that national or local COVID-19 guidelines recommended
- 228 mainly the use of N95/FFP2 respirators (120/267; 44.9%), followed by surgical masks
- 229 (77/267; 28.8%) or a combination of the two, respectively (39/267; 14.6%), and
- 230 powered air-purifying respirators (PAPR) (21/267; 7.9%). Variations existed within
- the 6 regions (Table 3). In Africa and Western Pacific regions, N95/FFP2 respirators
- and surgical masks (36/85; 42.3% and 6/14; 42.8%, respectively) were mainly
- 233 recommended. In Europe, the Americas and Eastern Mediterranean, N95/FFP2
- respirators were recommended according to more than half of respondents (55.8%,
- 235 52% and 70%, respectively). The use of PAPR was recommended in Africa (8/85;
- 236 9.4%) and Europe (12/68; 17.6%) P = .15.
- 237

238 Gown

- 239 Most respondents reported the use of long-sleeve water-repellent or resistant gowns
- 240 (170/242; 70%). By contrast, Southeast Asia reported a variety of recommended
- 241 gowns to be used, i.e. long-sleeve water-resistant (38.3%), short-sleeved plastic gown
- and a combination of both long-sleeve water-resistant and short-sleeved plastic gown
- 243 (26.6%) concurrently (Table 3).

244

245 Head protection

- More than half of respondents (56·3%) reported the use of a cap that covers the head only, while 43·6% used a cap that covers both head and neck (Table 3). There was a significant regional variation in their recommendations for the use of had protection (P < 01) (Table 3).
- 250
- 251 Eye protection
- 252 Overall, guidelines recommended the use of eye protection (72.2%; 95% CI, 68-77)
- 253 (Table 2). More than half (56%) of respondents reported the use of a disposable face
- shield while 28.2% recommended the use of goggles in the guidelines with significant regional differences (P < 01) (Table 3).
- 256
- _...
- 257 *Gloves*
- 258 The highest recommendation was reported for single-use disposable gloves (79.5%).
- 259 By contrast, double gloving was recommended by 17.5%: Africa, 30.1%; Europe,
- 260 20.5%; and Western Pacific, 15.3% (P < 01) (Table 3).
- 261
- 262 Shoe cover
- 263 More than half of respondents (58.9%) reported that guidelines recommended the use
- of some type of shoe covers. Of note, this was higher in Southeast Asia (70.3%) than
- in other regions (P < 01) (Table 3).
- 266
- 267 **Training**
- 268 Training sessions for HCWs concerning the appropriate and safe use of PPE were
- reported to happen by most respondents (235; 86·2%; 95% CI, 82·6-90·7) (Table 2,
- Fig. 1) with higher frequencies reported in HICs (74/79; 93.6%; 95% CI, 88.3-99) and

- 271 UMICs (83/88; 99%; 95% CI, 89·4-99·1) than in LICs (30/48; 62·5%; 95% CI, 62·5272 76·2) (P <·01) (figure 2).
- 273
- 274

275 COVID-19 and PPE supplies

276 When asked about the availability of PPE supplies, 163 of 339 (48%; 95% CI, 42.7-

277 53.4) respondents reported a shortage of supplies (64.2% [36/56; 95% CI, 51.7-76.8]

278 in LICs compared with 27.4% [31/113; 95% CI, 19.2-35.6] in HICs). Shortages were

- reported commonly in Southeast Asia (51/72; 70%; 95% CI, 60·3-81·3) and Africa
- 280 (65/113; 57.5%; 95% CI, 48.4-66.6). Shortage of facemasks was reported across all
- regions (Africa, 25.6%; the Americas, 21.2%; Eastern Mediterranean, 6.6%; Europe,

282 20.6% and Southeast Asia, 37.5%), except the Western Pacific (0%). Additional PPE

- supplies have been ordered across all regions (Africa, 19.4%; the Americas, 30.3%;
- Eastern Mediterranean, 40%; Europe, 33.7%; Southeast Asia 73.6%; and the Western
- Pacific 64.2%). However, increasing the PPE stockpile as part of the COVID-19
- preparedness plan was only reported in 12% of institutions (41/339), with more in
- HICs (19%; 22/113) than LICs (7%; 4/56). Distribution of PPE supplies was
- organized by the government (i.e. ministry of health) in 24.1% of institutions
- 289 (82/339), while only 19.4% (66/339) of facilities could order as much as necessary.
- 290 Of note, 44.2% (150/339) were not aware of the distribution procedure of PPE
- supplies at their institution.
- 292

293 Environmental Decontamination

- 294 Most respondents (199/270; 73.7%; 95% CI, 68.4-78.9) included hypochlorite
- disinfectant for environmental decontamination. Approximately one-third (100/270;

- 296 37.4%; 95% CI, 31.2-42.8) used automated room disinfection system technology at
- their institutions, such as hydrogen peroxide vapor and ultraviolet light (Table 2).
- 298 Among these, 12.5% (6/48; 95% CI, 3.1-21.8) were in LICs compared with 35.9%
- 299 (28/78; 95% CI, 25·2-46·5) in HICs (figure 1).
- 300

301 Community Preparedness

- 302 Less than one-third (69/253; 27.2%; 95% CI, 21.7-32.7) believed that community
- 303 preparedness was adequate, with the lowest frequencies reported in Southeast Asia
- 304 (9/63; 14·2%) and Africa (18/87; 20·6%) (P = .003), and a higher preparedness in
- 305 HIC (36/71; 50.7%) than in LICs (10/45; 22.2%) (P < 01). More than half (144/270;
- 306 53.3; 95% CI, 47.3-59.2) of respondents reported that PPE use for COVID-19 was
- 307 recommended in the community, mainly in Southeast Asia 77.2% (figure 2).

308

309 Overuse/misuse of supplies

- 310 More than half (149/253; 58.8%; 95% CI, 52.3-64.9) of respondents agreed that there
- 311 was an overuse/misuse of PPE, with a significant variation according to region (P <
- 312 \cdot 05) and income level (*P* < \cdot 001). Among these, 74 \cdot 3% (188/253; 95% CI, 68 \cdot 9-79 \cdot 6)
- 313 believed that the use and heightened focus on wearing facemasks creates a misplaced
- 314 feeling of safety, possibly reducing attention on other IPC measures, such as hand
- 315 hygiene. Fifty percent of respondents (95% CI 43.6-55.9) agreed that there was a
- 316 possible overuse/misuse of disinfectants in the community (figure 2).

317

318 Media exposure

- 319 The belief that opinions expressed by the media influenced the choices made for
- 320 national/local guidelines or the preparedness plans for COVID-19 was confirmed by

- 321 41.5% (105/252; 95% CI, 35.4-47.5) of respondents. More than half (161/253; 63.6%;
- 322 95% CI, 57.7-69.5) also believed that national/local guidelines were based
- 323 predominantly on maximum security, rather than on evidence-based
- 324 recommendations. HICs were more likely than LICs to report sufficient preparedness
- 325 (51/71; 71·8%; 95% CI, 61·3-82·2 vs 14/45; 31%; 95% CI, 17·5-44·6; *P* <·01) (Fig.
- 326 2).

327 Discussion

- 328 The COVID-19 pandemic has raised international concern prompting IPC
- 329 professionals to better control transmission and mitigate potential consequences. Our
- 330 exploratory survey was initiated less than 4 weeks after WHO's Public Health
- 331 Emergency of International Concern declaration on 30 January 2020 to provide
- 332 insight into the state of COVID-19 IPC preparedness worldwide. The vast majority of
- 333 respondents believed that preparedness guidelines were based on safety-maximized
- 334 procedures rather than on evidence-based recommendations; thus, uncertainties
- regarding the transmission modes of COVID-19 continue to generate
- 336 controversy.[1]['][15]
- 337

338 Our results show a wide variation of PPE recommendations, with predominantly the 339 use of N95/FFP2 respirators only or of surgical masks only or in combination with 340 respirators in specific situations. At the height of the outbreak, uncertainties about 341 transmission led many institutions to impose airborne precautions while considerable 342 variation was observed amongst international guidelines. The main transmission 343 modes of COVID-19 virus occur via respiratory droplets and contact [2,11,16] and 344 contact and droplet precautions were effective to control the MERS-CoV outbreak in 345 a haemodialysis unit in Saudi Arabia[10] and SARS in Hong Kong.[17]['][18] Aerosol346 generating procedures have been associated with the incidence of transmission of 347 coronaviruses.[19] Mainly guidelines do not recommend the use of shoe covers and 348 the transmission risk from contaminated footwear is likely low.[20] However, PPE 349 guidelines for HCWs in China recommend the use of shoe covers.[21] More 350 uniformity is needed at the international level on PPE recommended for care of 351 suspected or confirmed COVID-19 patients, based on available evidence and the 352 most effective IPC strategies.

353

354 At the time of the survey, most respondents were engaged in providing training to 355 HCWs on the appropriate and safe use of PPE, although lower frequency of training 356 were reported in LMICs. Recent healthcare-associated infections and deaths among 357 HCWs in China[12] and Italy[13] have emphasized the importance of training in 358 appropriate PPE use, particularly in performing a fit test of a particulate respirator, 359 safe PPE doffing and appropriate hand hygiene and use of gloves.[22] SARS infection 360 transmission among HCWs was associated with an inadequate compliance with PPE, 361 lack of understanding of IPC procedures and less than 2 h of infection control 362 training.[8] Although the importance of fit testing has been highlighted, national 363 standards vary widely and few documents explain the procedure in detail.[23] In some 364 countries, fit testing is required anually or before use, while in others it is not a 365 requirement, or fully absent, even though it has been shown that the efficacy of 366 respirator use improves after fit testing is performed [24]. 367 368 Hands-on training sessions on the use and compliance with PPE precautions and hand 369 hygiene compliance monitoring have been recommended as key measures.[22] HCWs 370 not trained in safe PPE doffing run the risk of accidental self-contamination, as

371 reported during the Ebola outbreak.[9] Innovative approaches to training are
372 important to mitigate the risk of viral self-contamination, suggesting that a rigorous
373 process must be designed, combined with standardized training.[25,26] The PPE
374 doffing process is critical to keep HCWs safe and further research on the science of
375 human factors and HCW behavior with respiratory protection safety is needed.

376

377 Shortage of PPE has become a global concern; 48% of respondents reported a 378 shortage of PPE across all regions, notably facemasks, with higher frequencies in 379 LMICs. Importantly, this shortage jeopardizes outbreak response strategies by 380 impeding appropriate and safe action to combat COVID-19 spread. An increasing 381 need for PPE supplies worldwide remains unmet and places HCWs and patient safety 382 under threat. Protection of HCWs should be prioritized and healthcare facilities must 383 have the necessary equipment. Political leaders and health authorities need to urgently 384 seek solutions and develop contingency plans to reserve and allocate resources where 385 these are needed the most. Increasing the PPE stockpile as part of the COVID-19 386 preparedness plan was only reported in 12% of facilities. While HICs have 387 established IPC programmes and yet are faced with deficient supplies, LICs may not 388 have the resources necessary to fight the current pandemic. WHO is undertaking 389 major efforts to coordinate the Emergency Global Supply Chain System facilitating 390 the purchase and shipment of PPE and medical supplies across the globe; as of 7 391 April, millions of pieces of PPE were shipped to 133 countries.[27] 392 Local production of alcohol-based hand rub using the WHO-recommended 393 formulation [28] has been reported in many countries in an attempt to replace the 394 current shortage. Some facilities are also considering reprocessing and reuse of

395	single-use PPE.[29] WHO has provided guidance of rational use of PPE including
396	considerations pertaining to reprocessing and reuse in case of severe shortage.[30]
397	

398	The survival of coronaviruses on environmental surfaces and the impact of
399	environmental contamination on healthcare-associated outbreaks as a mechanism of
400	transmission argue for enhanced environmental hygiene.[20,31,32] A chlorine-based
401	surface disinfectant was used by most participating facilities, but there appears to be
402	an infrequent use of automated room disinfection system technology. Automated
403	disinfection system technology may be more accurate as it diminishes reliance on the
404	operator.[33] Decontamination of high-touch surfaces as a potential source of
405	transmission needs to be considered.

406 Limitations

In the context of global health with increased attention to the COVID-19 epidemic
evolving and a situation that is rapidly changing, our specific intent was to provide a
snapshot of the state of affairs of IPC implemented measures less than four weeks
after WHO's declaration of a public health emergency of international concern and
while it had been declared a global pandemic. Since then, IPC preparedness measures

- 412 in healthcare facilities across countries have intensified and therefore it will be
- 413 interesting to assess with a follow-up survey.

414 Our study has limitations. First, this is a voluntary survey consisting of self-selected

- 415 participants whose perceptions and opinions might not be entirely representative for
- 416 healthcare facilities of a country and there was no validation method of the

417 participants' data entry. Second, most responses were from tertiary-care healthcare

- 418 facilities, which might suggest an overrepresentation of these settings. However,
- 419 tertiary-care hospitals have a central role in preparedness activities for emerging

420 infectious diseases and our results provide important information on their state of 421 preparedness. Third, some of the questions in our survey remained unanswered ('I 422 don't know') by a proportion of participants as depicted in Table 2 and 3, likely due to 423 some topics not having relevance to the local context of study participants. Fourth, 424 due to time and resource constraints the survey was made available only in English 425 and Chinese. Finally, the questions of the survey were not formally validated, since 426 the survey items were based mainly on the WHO COVID-19 global research roadmap 427 priorities that had been identified. Regardless of these limitations, the study provides 428 some important insight on necessary IPC measures that need to be considered to 429 scale-up preparedness to combat COVID-19.

430 Conclusion

431 Our findings, including identified concerns, may help to provide direction to improve 432 preparedness in countries and prioritization of critical actions. The COVID-19 global 433 pandemic has shown the importance of building more resilient healthcare systems 434 with effective IPC as key to avoid or mitigate outbreaks impact. Results revealed lack 435 of guidelines and, when available, large variations exist in recommendations. Health 436 organizations should jointly evaluate the available evidence and develop a uniform 437 policy on the appropriate PPE to be used. Strengthening of coordinated international 438 efforts is urgent to address the challenges related to the major PPE shortage in 439 healthcare facilities, particularly the lack of resources in low-income settings, and to 440 improve reliable communication through the media.

441

442 Acknowledgments

- 443 We are greatly indebted to all colleagues and members of the International Society of
- 444 Antimicrobial Chemotherapy on Infection Prevention and Control (ISAC-IPC)
- 445 Working Group and Infection Control Africa Network (ICAN) who participated in
- 446 this survey and for contributions to the questionnaire.
- 447

448 **Contributors**

- 449 ET, JH, BA and AV were involved in study design and implementation. ET and JH
- 450 contributed equally to the work. ET, JH, BG, KM, VCCC, SCW, AW, FO, AV
- 451 undertook data collection. ET and JH did data analysis and made the figures and
- 452 tables. ET, JH, BA, BG, AW, VCCC, SCW, KM, FO and AV were involved in data
- 453 interpretation and study coordination and contributed to writing and reviewing the
- 454 manuscript. All authors approved the final version for publication.
- 455 **Funding** This research received no specific grant from any funding agency in the
- 456 public, commercial or not-for-profit sectors.
- 457 **Competing interests** None declared.

458 **Disclaimer**

- 459 The opinions expressed in this Article are those of the authors and do not reflect the
- 460 official position of WHO. WHO takes no responsibility for the information provided
- 461 or the views expressed in this article.
- 462 **Ethical approval** This study was exempted by the Radboud University Medical
- 463 Center (The Netherlands) as it did not fall within the remit of the Medical Research
- 464 Involving Human Subjects Act (NL2020-6262).

References

467	[1]	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus
468		from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
469		https://doi.org/10.1056/NEJMoa2001017.
470	[2]	Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial
471		cluster of pneumonia associated with the 2019 novel coronavirus indicating
472		person-to-person transmission: a study of a family cluster. Lancet
473		2020;395:514-23. https://doi.org/10.1016/S0140-6736(20)30154-9.
474	[3]	World Health Organization. Coronavirus disease 2019 (COVID-19). Situation
475		report 90. Geneva, Switzerland: 2020.
476	[4]	World Health Organization. Statement on the second meeting of the
477		International Health Regulations (2005) Emergency Committee regarding the
478		outbreak of novel coronavirus (2019-nCoV). Geneva: n.d.
479	[5]	WHO Director-General's opening remarks at the media briefing on COVID-19
480		- 11 March 2020 n.d. https://www.who.int/dg/speeches/detail/who-director-
481		general-s-opening-remarks-at-the-media-briefing-on-covid-1911-march-
482		2020 (accessed April 16, 2020).
483	[6]	GLOPID-R and World Health Organization. COVID 19 Public Health
484		Emergency of International Concern (PHEIC) Global research and innovation
485		forum: towards a research roadmap. Geneva, 11-12 February: n.d.
486	[7]	Storr J, Twyman A, Zingg W, Damani N, Kilpatrick C, Reilly J, et al. Core
487		components for effective infection prevention and control programmes: New
488		WHO evidence-based recommendations. Antimicrob Resist Infect Control
489		2017;6. https://doi.org/10.1186/s13756-016-0149-9.
490	[8]	Lau JTF, Fung KS, Wong TW, Kim JH, Wong E, Chung S, et al. SARS
491		Transmission among Hospital Workers in Hong Kong. Emerg Infect Dis
492		2004;10:280-6. https://doi.org/10.3201/eid1002.030534.
493	[9]	World Health Organization. Ebola Response Roadmap Situation Report 1
494		Summary. n.d.
495	[10]	Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DAT, et
496		al. Hospital outbreak of middle east respiratory syndrome coronavirus. N Engl
497		J Med 2013;369:407–16. https://doi.org/10.1056/NEJMoa1306742.
498	[11]	Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of

499		138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia
500		in Wuhan, China. Jama 2020:1–9. https://doi.org/10.1001/jama.2020.1585.
501	[12]	
502	[]	with novel coronavirus disease 2019 (COVID-19) in China. J Hosp Infect
503		2020. https://doi.org/10.1016/j.jhin.2020.03.002.
504	[13]	Istituto Superiore di Sanità [Higher Institute of Health]. Sorveglianza integrata
505	[]	COVID-19 in Italia. n.d.
506	[14]	
507		economies. 2019.
508	[15]	
509		2019 novel coronavirus. Influenza Other Respi Viruses 2020:irv.12735.
510		https://doi.org/10.1111/irv.12735.
511	[16]	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
512		patients infected with 2019 novel coronavirus in Wuhan, China. Lancet
513		2020;395:497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
514	[17]	Seto W, Tsang D, Yung R, Ching T, Ng T, Ho M, et al. Effectiveness of
515		precautions against droplets and contact in prevention of nosocomial
516		transmission of severe acute respiratory syndrome (SARS). Lancet
517		2003;361:1519-20. https://doi.org/10.1016/S0140-6736(03)13168-6.
518	[18]	Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA,
519		et al. Physical interventions to interrupt or reduce the spread of respiratory
520		viruses. Cochrane Database Syst Rev 2011.
521		https://doi.org/10.1002/14651858.CD006207.pub4.
522	[19]	Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating
523		procedures and risk of transmission of acute respiratory infections to healthcare
524		workers: A systematic review. PLoS One 2012;7.
525		https://doi.org/10.1371/journal.pone.0035797.
526	[20]	Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, Surface
527		Environmental, and Personal Protective Equipment Contamination by Severe
528		Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a
529		Symptomatic Patient. Jama 2020:3-5. https://doi.org/10.1001/jama.2020.3227.
530	[21]	National Health Commission of the People's Republic of China. Technical
531		guidelines for the prevention and control of new coronavirus infections in
532		medical institutions (first edition). n.d.

533	[22]	Cheng VCC, Wong S-C, Chen JHK, Yip CCY, Chuang VWM, Tsang OTY, et
534		al. Escalating infection control response to the rapidly evolving epidemiology
535		of the Coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong
536		Kong. Infect Control Hosp Epidemiol 2020;2019:1–24.
537		https://doi.org/10.1017/ice.2020.58.
538	[23]	World Health Organization. How to perform a particulate respirator seal check
539		n.d. https://www.who.int/csr/resources/publications/respiratorsealcheck/en/
540		(accessed April 8, 2020).
541	[24]	Chughtai AA, Seale H, Macintyre CR. Availability, consistency and evidence-
542		base of policies and guidelines on the use of mask and respirator to protect
543		hospital health care workers: A global analysis. BMC Res Notes 2013;6:1.
544		https://doi.org/10.1186/1756-0500-6-216.
545	[25]	Casanova L, Alfano-Sobsey E, Rutala WA, Weber DJ, Sobsey M. Virus
546		transfer from personal protective equipment to healthcare employees' skin and
547		clothing. Emerg Infect Dis 2008;14:1291–3.
548		https://doi.org/10.3201/eid1408.080085.
549	[26]	Mumma JM, Durso FT, Casanova LM, Erukunuakpor K, Kraft CS, Ray SM, et
550		al. Common Behaviors and Faults When Doffing Personal Protective
551		Equipment for Patients with Serious Communicable Diseases. Clin Infect Dis
552		2019;69:S214-20. https://doi.org/10.1093/cid/ciz614.
553	[27]	World Health Organization. Strategic preparedness and response plan. Geneva,
554		Switzerland: 2020.
555	[28]	World Health Organization. Guide to local production: WHO-recommended
556		handrub formulations. n.d.
557	[29]	Cheng VCC, Wong SC, Kwan GSW, Hui WT YK. Disinfection of N95
558		respirators by ionized hydrogen peroxide in pandemic coronavirus disease
559		2019 (COVID-19) due to SARS-CoV-2. J Hosp Infect 2020.
560		https://doi.org/10.1016/j.jhin.2020.04.003.
561	[30]	World Health Organization. Rational use of personal protective equipment for
562		coronavirus disease (COVID-19). Interim guidance. 27 February 2020. vol.
563		2019. Geneva, Switzerland: 2020.
564	[31]	Santarpia JL, Rivera DN, Herrera V, Morwitzer MJ, Creager H, Santarpia GW,
565		et al. Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at
566		the University of Nebraska Medical Center. MedRxiv

- 567 2020:2020.03.23.20039446. https://doi.org/10.1101/2020.03.23.20039446. 568 [32] Chia PY, Coleman KK, Tan YK, Ong SWX, Gum M, Lau SK, et al. Detection 569 of Air and Surface Contamination by Severe Acute Respiratory Syndrome 570 Coronavirus 2 (SARS-CoV-2) in Hospital Rooms of Infected Patients. 571 MedRxiv 2020:2020.03.29.20046557. 572 https://doi.org/10.1101/2020.03.29.20046557. 573 [33] Otter JA, Yezli S, Perl TM, Barbut F, French GL. The role of "no-touch" 574 automated room disinfection systems in infection prevention and control. J 575 Hosp Infect 2013;83:1–13. https://doi.org/10.1016/j.jhin.2012.10.002. 576
- 577

578	Figure legends
579	
580	
581	
582	
583	Figure 1: Presence of COVID-19 Guidelines and the Most Critical Infection
584	Prevention and Control Measures Recommended as Identified Among Survey
585	Respondents, Stratified by Country Income Level.
586	HIC, high-income country; UMIC, upper-middle income country; LMIC, lower-
587	middle income country; LIC, low-income country; PPE, personal protective
588	equipment.
589	
590	Figure 2: Perceived Opinion of the Level of Preparedness of Institutions for COVID-
591	19 Among Survey Respondents, Stratified by Country Income Level.
592	HIC, high-income country; UMIC, upper-middle income country; LMIC, lower-
593	middle income country; LIC, low-income country; PPE, personal protective
594	equipment; IPC, infection prevention and control.
595	

- 597 Supplementary File
- **1. STROBE checklist.**
- **2.** Survey Instrument.

Table 1 Characteristics of Survey Respondents

Characteristic			Ν	o. of Res	pondents (%)			
Geographical region									
	Africa			113	(33-33)				
	Europe			92 (27.14)				
	Southeast Asia			72 (21.24)				
	Americas			33	(9.73)				
	Eastern Mediterranean			15	(4.42)				
	Africa Europe Southeast Asia Americas Eastern Mediterranean Western Pacific High income Upper middle income Lower middle income Low income Physician Nurse Infection control practitioner Microbiologist Pharmacist Other Public health specialists ity			14	(4.13)				
Income level									
	High income			113	(33-33)				
	Upper middle income			99 (29.20)				
	stic al region Africa Europe Southeast Asia Americas Eastern Mediterranean Western Pacific el High income Upper middle income Lower middle income Low income Low income Physician Nurse Infection control practitioner Microbiologist Pharmacist Other Public health specialists Facility Facility Primary-level health care facility Secondary-level health care facility Tertiary-level health care facility Other (please specify) e			71 (20.94)				
	Low income			56 (16.52)				
Profession									
	Physician			154	(45.43)				
	Nurse			95 (28.02)				
	Infection control practitioner		28 (8.26)						
	Microbiologist	26 (7.67)							
	Pharmacist	14 (4.13)							
	Other		11 (3·24)						
	Public health specialists	11 (3·24)							
Healthcare Facility									
	$\begin{tabular}{ c c c c c } \hline Africa & 113 (33:33) \\ \hline Europe & 92 (27:14) \\ \hline Southeast Asia & 72 (21:24) \\ \hline Americas & 33 (9:73) \\ \hline Eastern Mediterranean & 15 (4:42) \\ \hline Western Pacific & 14 (4:13) \\ \hline \\ $								
	Secondary-level health care facility			63 (18.58)				
	Tertiary-level health care facility		156 (46.02)						
	Other (please specify)			47 (13.86)				
Hospital size		min		mean	median		ma		
	< 200	0	18	284-21	50	150	250		
	200 - 800	21	200	483.51	300	462.5	300		
	300 - 1500	0	460	865-31	800	1000	44(
	Other	0	0	288.91	0	89	300		

 Table 2. Geographical comparison of healthcare facilities and IPC preparedness for patients with COVID-19, results from survey of representatives from 339 healthcare facilities in 63 countries worldwide, February-March

	No [.] (%) of	Comparison between regions						
	Respondents	Africa	Americas	East Mediterranean	Europe	South-East Asia	Western Pacific	
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	P-value
COVID-19 Guidelines								
National guidelines	226 (66.67)	53 (46.9)	22 (66.67)	13 (86.67)	65 (70.65)	60 (83.33)	13 (92.86)	<0.001
Local guidelines	182 (53.69)	40 (35.4)	21 (63.64)	8 (53-33)	42 (45.65)	62 (86-11)	9 (64-29)	<0.001
Guidelines recommend use of PPE								
Guidelines address PPE	214 (63-13)	60 (53.1)	20 (60.61)	9 (60)	51 (55-43)	63 (87.5)	11 (78.57)	<0.001
Facemask	272 (80.24)	87 (76-99)	25 (75.76)	11 (73-33)	70 (76.09)	65 (90.28)	14 (100)	0.06
Gown	251 (74.04)	81 (71.68)	22 (66.67)	9 (60)	65 (70.65)	60 (83-33)	14 (100)	0.04
Cap	182 (64-31)	66 (68-75)	8 (29.63)	5 (50)	42 (60)	57 (86.36)	4 (28.57)	<0.001
Eye protection	245 (72.27)	75 (66-37)	22 (66.67)	10 (66.67)	65 (70.65)	60 (83-33)	13 (92.86)	0.07
Gloves	266 (97.08)	90 (96.77)	26 (96-3)	10 (100)	65 (95.59)	62 (98.41)	13 (100)	0.004
Preparedness effort								
Hand hygiene	259 (96.28)	86 (93-48)	24 (92-31)	10 (100)	63 (98-44)	65 (98.48)	11 (100)	0.34
Training HCWs	235 (86.72)	67 (72.83)	24 (85.71)	10 (100)	59 (92-19)	64 (96.97)	11 (100)	<0.001
PPE in community	144 (53-33)	51 (55-43)	8 (29.63)	1 (10)	27 (42-19)	51 (77.27)	6 (54-55)	<0.001
PPE in outpatient setting	243 (91-35)	80 (86.96)	21 (84)	10 (100)	56 (90-32)	65 (98.48)	11 (100)	0.07
Environmental decontamination								_
Use of Hypochlorite	199 (73-7)	74 (80.43)	13 (48-15)	5 (50)	40 (62.5)	61 (92.42)	6 (54-55)	<0.001
Automated disinfection system	100 (37.04)	12 (13.04)	6 (22-22)	4 (40)	25 (39.06)	52 (78.79)	1 (9.09)	<0.001

Table 3 Protective Equipment	(PPE) included in national	or local COVID-19 guidelines

	No [.] (%) of	Comparison between regions						
	Respondents	Africa	Americas	East Mediterranean	Europe	South-East Asia	Western Pacific	
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	P-value
Face mask	N = 267							
FFP1	6 (2.25)	2 (2.35)	0 (0)	0 (0)	3 (4.41)	1 (1.54)	0 (0)	0.16
N95/FFP2	120 (44.94)	36 (42.35)	13 (52)	7 (70)	38 (55.88)	20 (30.77)	6 (42.86)	< 0.001
Respirators	21 (7.87)	8 (9.41)	1 (4)	0 (0)	12 (17.65)	0 (0)	0 (0)	< 0.00
Surgical mask & N95/FFP2	39 (14.61)	1 (1-18)	1 (4)	0 (0)	2 (2.94)	33 (50.77)	2 (14·29)	< 0.00
Surgical mask	77 (28.84)	36 (42.35)	10 (40)	3 (30)	11 (16-18)	11 (16.92)	6 (42.86)	< 0.00
Other	4 (1.5)	2 (2.35)	0 (0)	0 (0)	2 (2.94)	0 (0)	0 (0)	< 0.00
Gown type:	N = 242							
Short-sleeved plastic	27 (11.16)	4 (5.41)	2 (9.09)	0 (0)	1 (1.59)	20 (33-33)	0 (0)	< 0.00
Long sleeve water repellant	170 (70.25)	52 (70.27)	20 (90.91)	8 (88.89)	55 (87-3)	23 (38-33)	12 (85.71)	< 0.00
Coverall	29 (11.98)	18 (24.32)	0 (0)	1 (11-11)	7 (11-11)	1 (1.67)	2 (14·29)	< 0.00
Long-sleeved-water resistant & Short-sleeved plastic	16 (6.61)	0 (0)	0 (0)	0 (0)	0 (0)	16 (26.67)	0 (0)	< 0.00
Cap type:	N = 181							
Cap covering head and neck	79 (43.65)	44 (67.69)	4 (50)	2 (40)	19 (45-24)	6 (10.53)	4 (100)	< 0.00
Cap covering the head only	102 (56.35)	21 (32·31)	4 (50)	3 (60)	23 (54.76)	51 (89.47)	0 (0)	< 0.00
Eye protection:	N = 241							
"Ski"-googles	68 (28.22)	17 (23-29)	5 (22.73)	1 (10)	15 (23.44)	29 (48.33)	1 (8.33)	< 0.00
Face shield	135 (56.02)	47 (64.38)	8 (36-36)	8 (80)	37 (57.81)	28 (46.67)	7 (58-33)	< 0.00
Other	38 (15.77)	9 (12.33)	9 (40.91)	1 (10)	12 (18.75)	3 (5)	4 (33-33)	< 0.00
Gloves:	N = 274							
No gloves	8 (2.92)	3 (3.23)	1 (3.7)	0 (0)	3 (4.41)	1 (1.59)	0 (0)	0.22
Double gloving	48 (17.52)	28 (30.11)	1 (3.7)	1 (10)	14 (20.59)	2 (3.17)	2 (15.38)	< 0.00
Single pair disposable	218 (79.56)	62 (66.67)	25 (92.59)	9 (90)	51 (75)	60 (95.24)	11 (84.62)	< 0.00
Shoe cover:	N = 275							
Shoe and lower leg cover	50 (18.18)	30 (32.26)	0 (0)	0 (0)	11 (16-18)	5 (7.81)	4 (30.77)	< 0.00
Shoe cover	99 (36)	30 (32.26)	6 (22-22)	2 (20)	16 (23.53)	45 (70.31)	0 (0)	< 0.00
No shoe cover	126 (45.82)	33 (35.49)	21 (77.77)	8 (80)	41 (60.29)	14 (21.87)	9 (69.23)	< 0.00

PPE: Pers**634**protective equipment; PAPR: powered air-purifying respirators.

647
648
649



